Vol. VI · ii Metabolic 2 min read
Semaglutide or Tirzepatide: What the Second Receptor Changes
Tirzepatide works on two incretin pathways. The difference is not simply more of the same.
Semaglutide acts on the GLP-1 receptor. Tirzepatide acts on GLP-1 and on GIP, a second incretin hormone with its own effects on insulin secretion and fat metabolism. In practice the dual mechanism produces greater average weight loss at comparable tolerability, but it is not simply a stronger version of the same drug — and that distinction has a clinical use.
What an incretin is
Incretins are hormones your gut releases after eating. They prompt insulin release in response to food and contribute to the signalling that tells your brain you have eaten enough.
GLP-1 is the better known of the two. GIP is the other, and it has its own effects on insulin secretion and on how fat tissue handles energy u2014 related to GLP-1's, but not identical.
One receptor or two
Semaglutide targets the GLP-1 receptor. Tirzepatide targets GLP-1 and GIP together, which is why it is described as a dual agonist.
In trials the dual mechanism produces greater average weight loss at broadly comparable tolerability. Averages describe populations, though, and the more useful clinical fact is that individual responses differ in ways the average conceals.
Mechanism is a reason to switch, not only a reason to escalate.
Why this is a reason to switch, not only to escalate
Patients who responded poorly to one sometimes respond well to the other. That is not what you would expect if the second were merely a stronger version of the first.
So when a patient stalls at a maximum tolerated dose, moving pathways is often more productive than pushing the same pathway harder. Mechanism is a reason to switch, not only a reason to escalate.
What is the same
Both are weekly subcutaneous injections with similar titration logic: start low, escalate on response and tolerability, settle at the lowest dose that still produces change.
The side-effect profiles overlap substantially, and gastrointestinal effects dominate both. Nothing about the second receptor removes the need for careful titration.
How the choice actually gets made
At review, on response u2014 not at intake, on preference. Starting history, tolerability, what you have already tried and what is available all feed into it.
A patient doing well on either has no clinical reason to switch. The distinction earns its keep when something is not working, which is precisely when knowing that two mechanisms exist is worth something.
Common questions
Is tirzepatide stronger than semaglutide?
Trials show greater average weight loss with the dual-agonist mechanism at broadly comparable tolerability. But it acts on a second receptor rather than being a higher dose of the same thing, and individual responses differ in ways an average conceals.
Can you switch from one to the other?
Yes, and it is a recognised clinical move. Patients who respond poorly to one sometimes respond well to the other, so switching pathways is often more productive than pushing the same pathway harder after a stall.
What does GIP actually do?
GIP is a second incretin hormone with its own effects on insulin secretion and on how fat tissue handles energy. Targeting it alongside GLP-1 is what distinguishes a dual agonist from a GLP-1 agonist alone.
Educational — not medical advice.